Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-2957.72%
operating margin TTM
-3477.44%
revenue TTM
15.11 Million
revenue per share TTM
0.13$
valuation ratios | |
|---|---|
| pe ratio | -10.59 |
| peg ratio | 30.61 |
| price to book ratio | 2.40 |
| price to sales ratio | 293.11 |
| enterprise value multiple | -9.04 |
| price fair value | 2.40 |
profitability ratios | |
|---|---|
| gross profit margin | 87.81% |
| operating profit margin | -3477.44% |
| pretax profit margin | -2957.72% |
| net profit margin | -2957.72% |
| return on assets | -20.61% |
| return on equity | -25.89% |
| return on capital employed | -25.85% |
liquidity ratio | |
|---|---|
| current ratio | 15.73 |
| quick ratio | 15.73 |
| cash ratio | 2.24 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 945.31 |
| days of payables outstanding | 2,325.50 |
| cash conversion cycle | -1,380.19 |
| receivables turnover | 0.39 |
| payables turnover | 0.16 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -44.24 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.40 |
| cash per share | 11.69 |
| operating cash flow per share | -2.34 |
| free cash flow operating cash flow ratio | 1.02 |
| cash flow coverage ratios | -44.24 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -42.58 |
Frequently Asked Questions
When was the last time Avidity Biosciences, Inc. (NASDAQ:RNA) reported earnings?
Avidity Biosciences, Inc. (RNA) published its most recent earnings results on 30-09-2024.
What is Avidity Biosciences, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Avidity Biosciences, Inc. (NASDAQ:RNA)'s trailing twelve months ROE is -25.89%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Avidity Biosciences, Inc. (RNA) currently has a ROA of -20.61%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did RNA's net profit margin stand at?
RNA reported a profit margin of -2957.72% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is RNA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 15.73 in the most recent quarter. The quick ratio stood at 15.73, with a Debt/Eq ratio of 0.00.